US 12,275,996 B2
Head and neck squamous cell carcinoma assays
Bert Vogelstein, Baltimore, MD (US); Kenneth W. Kinzler, Baltimore, MD (US); Luis Diaz, Ellicot City, MD (US); Nickolas Papadopoulos, Towson, MD (US); Nishant Agrawal, Baltimore, MD (US); Yuxuan Wang, Baltimore, MD (US); and Simeon Springer, Baltimore, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Jan. 27, 2022, as Appl. No. 17/586,101.
Application 17/586,101 is a continuation of application No. 15/739,610, granted, now 11,268,153, previously published as PCT/US2016/037793, filed on Jun. 16, 2016.
Claims priority of provisional application 62/182,757, filed on Jun. 22, 2015.
Prior Publication US 2022/0220563 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of detecting oropharynx, larynx, or hypopharynx Head and Neck Squamous Cell Carcinoma comprising:
assaying a plasma sample from a subject comprising plasma DNA, wherein said assaying comprises performing PCR amplification and/or sequencing of said plasma DNA to detect the presence or absence of at least one mutation in at least two genes selected from the group consisting of: TP53, PIK3CA, CDKN2A, FBXW7, HRAS, and NRAS; and
assaying a saliva sample from the subject comprising saliva DNA, wherein said assaying comprises performing PCR amplification and/or sequencing of said saliva DNA to detect the presence or absence of at least one mutation in said at least two genes;
wherein the detection of a mutation in at least one of said at least two genes in the plasma DNA or in the saliva DNA is indicative of the presence of at least one Head and Neck Squamous Cell Carcinoma (HNSCC) selected from: oropharynx HNSCC, larynx HNSCC, and hypopharynx HNSCC.